Leonard Calabrese, DO; Madelaine Feldman, MD, FACR; Prof Iain McInnes, CBE, FRCP, PhD, FRSE, FMedSci
This activity is jointly provided by Global Education Group and Integritas Communications.
This activity is supported by an independent educational grant from Gilead Sciences, Inc.
Leonard H. Calabrese, DO
Professor of Medicine and Vice Chair
Department of Rheumatologic & Immunologic Disease
Cleveland Clinic Lerner College of Medicine
Madelaine Feldman, MD, FACR
President, Coalition of State Rheumatology Organizations
Clinical Assistant Professor of Medicine
Tulane University School of Medicine
Private Practice, The Rheumatology Group
New Orleans, Louisiana
Prof Iain B. McInnes CBE, FRCP, PhD, FRSE, FMedSci
Muirhead Chair of Medicine/Versus Arthritis Professor of Rheumatology
Director, ARUK Centre of Excellence for Rheumatoid Arthritis
Vice Principal and Head of College of Medical, Veterinary and Life Sciences
University of Glasgow
This expert roundtable activity will provide insights into the latest available evidence and recommendations for the optimal implementation of Janus kinase (JAK) inhibitor therapies within patient-centric RA management plans. A faculty panel of world-renowned rheumatologists will guide learners through the current RA treatment landscape, focusing on the latest efficacy and safety studies, real-world patient outcomes, updates to national/international treatment recommendations, and evolving COVID-19 guidance. Lastly, experts will help translate this evidence into same-day clinical practice and share their experiences in navigating barriers to effective individualized RA patient care.
This activity is designed to address the needs of rheumatologists and rheumatology specialist nurse practitioners (NPs) and physician assistants (PAs), with the overall program goal of improving the care of patients with rheumatoid arthritis (RA).
Upon completion of this activity, participants will be able to:
- Review the latest clinical trial evidence regarding JAK inhibitors for the treatment of RA, including efficacy and safety data
- Describe updates to RA treatment recommendations, best practices, and the evidence base for incorporating JAK inhibitors into the RA treatment algorithm
- Utilize effective strategies to safely and appropriately implement and monitor JAK inhibitor therapies while overcoming barriers to access
Physician Accreditation Statement
This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of Global Education Group (Global) and Integritas Communications. Global is accredited by the ACCME to provide continuing medical education for physicians.
Physician Credit Designation
Global Education Group designates this enduring material for a maximum of 0.75 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Disclosure of Conflicts of Interest
Global Education Group (Global) requires instructors, planners, managers, and other individuals and their spouses/life partners who are in a position to control the content of this activity to disclose any real or apparent conflict of interest they may have as related to the content of this activity. All identified conflicts of interest are thoroughly vetted by Global for fair balance, scientific objectivity of studies mentioned in the materials or used as the basis for content, and appropriateness of patient care recommendations.
The faculty reported the following financial relationships or relationships to products or devices they or their spouses/life partners have with commercial interests related to the content of this CME activity:
Leonard Calabrese, DO Consultant/Independent Contractor: Gilead Sciences, Inc., GlaxoSmithKline plc, Novartis Pharmaceuticals Corporation; Honoraria: AbbVie Inc., Horizon Therapeutics plc, Eli Lilly and Company, sanofi-aventis U.S. LLC, UCB S.A.
Madelaine Feldman, MD, FACR: Consultant/Independent Contractor: Bristol-Myers Squibb Company, Gilead Sciences, Inc.; Speakers Bureau: Eli Lilly and Company; Stock Shareholder: Celgene Corporation
Prof Iain McInnes, CBE, FRCP, PhD, FRSE, FMedSci: Consultant/Independent Contractor: Abbvie Inc., Bristol-Myers Squibb Company, Celgene Corporation, Gilead Sciences, Inc., Janssen Global Services, LLC, Eli Lilly and Company, Novartis Pharmaceuticals Corporation, Pfizer Inc., UCB S.A.; Grant/Research Support: Bristol-Myers Squibb Company, Celgene Corporation, Gilead Sciences, Inc., Janssen Global Services, LLC, Novartis Pharmaceuticals Corporation, UCB S.A.
The planners and managers reported the following financial relationships or relationships to products or devices they or their spouses/life partners have with commercial interests related to the content of this CME activity:
Lindsay Borvansky: Nothing to disclose
Andrea Funk: Nothing to disclose
Liddy Knight: Nothing to disclose
Ashley Cann: Nothing to disclose
Jim Kappler, PhD: Nothing to disclose
Celeste Collazo, MD: Nothing to disclose
Instructions to Receive Credit
In order to receive credit for this activity, the participant must score 75% or better on the posttest and complete the program evaluation.
Fee Information & Refund/Cancellation Policy
There is no fee for this educational activity.
Global Contact Information
For information about the accreditation of this program, please contact Global at 303-395-1782 or firstname.lastname@example.org.
Disclosure of Unlabeled Use
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the US Food and Drug Administration. Global Education Group (Global) and Integritas Communications do not recommend the use of any agent outside of the labeled indications.
The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of any organization associated with this activity. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.
Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed in this activity should not be used by clinicians without evaluation of patient conditions and possible contraindications or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.